Titre : Complément C3c

Complément C3c : Questions médicales fréquentes

Termes MeSH sélectionnés :

Administration, Intravenous

Questions fréquentes et termes MeSH associés

Diagnostic 5

#1

Comment mesurer le complément C3c ?

Le complément C3c est mesuré par un test sanguin spécifique en laboratoire.
Compléments Tests de laboratoire
#2

Quels tests sont associés au C3c ?

Les tests de C3c sont souvent associés à des dosages de C3 et C4.
Compléments Tests de laboratoire
#3

Quand évaluer le C3c ?

Le C3c est évalué lors de suspicion de maladies auto-immunes ou inflammatoires.
Maladies auto-immunes Inflammation
#4

Le C3c est-il un marqueur de maladie ?

Oui, des niveaux anormaux de C3c peuvent indiquer des pathologies sous-jacentes.
Marqueurs biologiques Pathologies
#5

Quel rôle joue le C3c dans le diagnostic ?

Le C3c aide à évaluer l'activité du système du complément dans diverses conditions.
Système du complément Diagnostic

Symptômes 5

#1

Quels symptômes sont liés à un faible C3c ?

Un faible C3c peut entraîner des infections fréquentes et des inflammations.
Infections Inflammation
#2

Un C3c élevé indique-t-il des symptômes ?

Un C3c élevé peut être associé à des symptômes d'inflammation ou d'infection.
Inflammation Infection
#3

Le C3c affecte-t-il la fatigue ?

Des niveaux anormaux de C3c peuvent contribuer à la fatigue liée à l'inflammation.
Fatigue Inflammation
#4

Y a-t-il des symptômes spécifiques au C3c ?

Non, le C3c n'a pas de symptômes spécifiques, mais reflète l'état immunitaire.
Système immunitaire Symptômes
#5

Le C3c est-il lié à des douleurs ?

Des niveaux élevés de C3c peuvent être associés à des douleurs inflammatoires.
Douleur Inflammation

Prévention 5

#1

Comment prévenir les anomalies du C3c ?

Maintenir un mode de vie sain et gérer les maladies chroniques aide à prévenir les anomalies.
Prévention Maladies chroniques
#2

Le vaccin influence-t-il le C3c ?

Les vaccins peuvent stimuler le système immunitaire, influençant potentiellement le C3c.
Vaccins Système immunitaire
#3

Y a-t-il des habitudes à éviter ?

Éviter le tabagisme et une mauvaise alimentation peut aider à maintenir un C3c normal.
Tabagisme Alimentation
#4

Le stress affecte-t-il le C3c ?

Oui, le stress chronique peut perturber le système immunitaire et affecter le C3c.
Stress Système immunitaire
#5

Des examens réguliers sont-ils nécessaires ?

Oui, des examens réguliers peuvent aider à détecter des anomalies du C3c tôt.
Examens médicaux Prévention

Traitements 5

#1

Comment traiter un faible C3c ?

Le traitement dépend de la cause sous-jacente, souvent par immunothérapie.
Immunothérapie Traitement
#2

Des médicaments affectent-ils le C3c ?

Oui, certains médicaments immunosuppresseurs peuvent réduire les niveaux de C3c.
Médicaments immunosuppresseurs Compléments
#3

Le C3c nécessite-t-il un suivi ?

Oui, un suivi régulier est recommandé pour surveiller les niveaux de C3c.
Suivi médical Compléments
#4

Peut-on augmenter le C3c naturellement ?

Une alimentation équilibrée et un mode de vie sain peuvent soutenir le système immunitaire.
Alimentation Système immunitaire
#5

Les transfusions affectent-elles le C3c ?

Oui, les transfusions peuvent influencer les niveaux de C3c en fonction des composants.
Transfusions sanguines Compléments

Complications 5

#1

Quelles complications peuvent survenir avec un C3c bas ?

Un C3c bas peut entraîner des infections récurrentes et des maladies auto-immunes.
Infections Maladies auto-immunes
#2

Un C3c élevé cause-t-il des complications ?

Oui, un C3c élevé peut être lié à des complications inflammatoires et des maladies chroniques.
Complications Inflammation
#3

Le C3c affecte-t-il la guérison des blessures ?

Des niveaux anormaux de C3c peuvent retarder la guérison en perturbant l'inflammation.
Guérison Inflammation
#4

Y a-t-il des risques de thrombose liés au C3c ?

Des niveaux élevés de C3c peuvent être associés à un risque accru de thrombose.
Thrombose Risques
#5

Le C3c influence-t-il les maladies cardiovasculaires ?

Oui, des niveaux anormaux de C3c peuvent être liés à un risque accru de maladies cardiovasculaires.
Maladies cardiovasculaires Risques

Facteurs de risque 5

#1

Quels facteurs augmentent le risque de C3c anormal ?

Les maladies auto-immunes, infections chroniques et certains médicaments augmentent le risque.
Facteurs de risque Maladies auto-immunes
#2

L'âge influence-t-il le C3c ?

Oui, l'âge peut affecter les niveaux de C3c, souvent en raison de changements immunitaires.
Âge Système immunitaire
#3

Le sexe joue-t-il un rôle dans le C3c ?

Oui, des différences hormonales peuvent influencer les niveaux de C3c entre les sexes.
Sexe Hormones
#4

Le mode de vie affecte-t-il le C3c ?

Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent affecter le C3c.
Mode de vie Alimentation
#5

Les antécédents familiaux influencent-ils le C3c ?

Oui, des antécédents familiaux de maladies immunitaires peuvent augmenter le risque de C3c anormal.
Antécédents familiaux Maladies immunitaires
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Complément C3c : Questions médicales les plus fréquentes", "headline": "Complément C3c : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Complément C3c : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-04", "dateModified": "2025-03-31", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Complément C3c" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Complément C3b", "url": "https://questionsmedicales.fr/mesh/D003179", "about": { "@type": "MedicalCondition", "name": "Complément C3b", "code": { "@type": "MedicalCode", "code": "D003179", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.124.486.274.250.260" } } }, "about": { "@type": "MedicalCondition", "name": "Complément C3c", "alternateName": "Complement C3c", "code": { "@type": "MedicalCode", "code": "D015932", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Marinos C Dalakas", "url": "https://questionsmedicales.fr/author/Marinos%20C%20Dalakas", "affiliation": { "@type": "Organization", "name": "Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA. mdalakas@med.uoa.gr." } }, { "@type": "Person", "name": "Shruti Chaturvedi", "url": "https://questionsmedicales.fr/author/Shruti%20Chaturvedi", "affiliation": { "@type": "Organization", "name": "Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA." } }, { "@type": "Person", "name": "Robert A Brodsky", "url": "https://questionsmedicales.fr/author/Robert%20A%20Brodsky", "affiliation": { "@type": "Organization", "name": "Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA." } }, { "@type": "Person", "name": "Keith R McCrae", "url": "https://questionsmedicales.fr/author/Keith%20R%20McCrae", "affiliation": { "@type": "Organization", "name": "Division of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH." } }, { "@type": "Person", "name": "Martin Kohn", "url": "https://questionsmedicales.fr/author/Martin%20Kohn", "affiliation": { "@type": "Organization", "name": "Institute of Medical Microbiology and Hospital Epidemiology, Medical School Hannover, Hannover, Germany." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Pharmacokinetics and tolerability of intranasal or intravenous administration of nalbuphine in infants.", "datePublished": "2022-09-13", "url": "https://questionsmedicales.fr/article/36100355", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/archdischild-2022-323807" } }, { "@type": "ScholarlyArticle", "name": "A case of intravenous iron administration resulting in cerebral edema expansion.", "datePublished": "2023-05-30", "url": "https://questionsmedicales.fr/article/37254070", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12883-023-03258-8" } }, { "@type": "ScholarlyArticle", "name": "Feasibility of periprocedural decision on the administration of intravenous contrast media in MRI for endometriosis.", "datePublished": "2023-06-25", "url": "https://questionsmedicales.fr/article/37392544", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ejrad.2023.110949" } }, { "@type": "ScholarlyArticle", "name": "Optimization of intravenous administration of hydroxocobalamin in pediatric emergencies - HYDROX-OPTIMIS study.", "datePublished": "2023-10-21", "url": "https://questionsmedicales.fr/article/37871551", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ienj.2023.101353" } }, { "@type": "ScholarlyArticle", "name": "Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Patients With Multiple Myeloma at Mayo Clinic Infusion Centers.", "datePublished": "2023-02-09", "url": "https://questionsmedicales.fr/article/36758192", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1200/OP.22.00421" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines du sang", "item": "https://questionsmedicales.fr/mesh/D001798" }, { "@type": "ListItem", "position": 5, "name": "Immunoprotéines", "item": "https://questionsmedicales.fr/mesh/D007162" }, { "@type": "ListItem", "position": 6, "name": "Protéines du système du complément", "item": "https://questionsmedicales.fr/mesh/D003165" }, { "@type": "ListItem", "position": 7, "name": "Complément C3", "item": "https://questionsmedicales.fr/mesh/D003176" }, { "@type": "ListItem", "position": 8, "name": "Complément C3b", "item": "https://questionsmedicales.fr/mesh/D003179" }, { "@type": "ListItem", "position": 9, "name": "Complément C3c", "item": "https://questionsmedicales.fr/mesh/D015932" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Complément C3c - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Complément C3c", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-04", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Complément C3c", "description": "Comment mesurer le complément C3c ?\nQuels tests sont associés au C3c ?\nQuand évaluer le C3c ?\nLe C3c est-il un marqueur de maladie ?\nQuel rôle joue le C3c dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D015932?mesh_terms=Administration,+Intravenous#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Complément C3c", "description": "Quels symptômes sont liés à un faible C3c ?\nUn C3c élevé indique-t-il des symptômes ?\nLe C3c affecte-t-il la fatigue ?\nY a-t-il des symptômes spécifiques au C3c ?\nLe C3c est-il lié à des douleurs ?", "url": "https://questionsmedicales.fr/mesh/D015932?mesh_terms=Administration,+Intravenous#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Complément C3c", "description": "Comment prévenir les anomalies du C3c ?\nLe vaccin influence-t-il le C3c ?\nY a-t-il des habitudes à éviter ?\nLe stress affecte-t-il le C3c ?\nDes examens réguliers sont-ils nécessaires ?", "url": "https://questionsmedicales.fr/mesh/D015932?mesh_terms=Administration,+Intravenous#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Complément C3c", "description": "Comment traiter un faible C3c ?\nDes médicaments affectent-ils le C3c ?\nLe C3c nécessite-t-il un suivi ?\nPeut-on augmenter le C3c naturellement ?\nLes transfusions affectent-elles le C3c ?", "url": "https://questionsmedicales.fr/mesh/D015932?mesh_terms=Administration,+Intravenous#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Complément C3c", "description": "Quelles complications peuvent survenir avec un C3c bas ?\nUn C3c élevé cause-t-il des complications ?\nLe C3c affecte-t-il la guérison des blessures ?\nY a-t-il des risques de thrombose liés au C3c ?\nLe C3c influence-t-il les maladies cardiovasculaires ?", "url": "https://questionsmedicales.fr/mesh/D015932?mesh_terms=Administration,+Intravenous#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Complément C3c", "description": "Quels facteurs augmentent le risque de C3c anormal ?\nL'âge influence-t-il le C3c ?\nLe sexe joue-t-il un rôle dans le C3c ?\nLe mode de vie affecte-t-il le C3c ?\nLes antécédents familiaux influencent-ils le C3c ?", "url": "https://questionsmedicales.fr/mesh/D015932?mesh_terms=Administration,+Intravenous#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment mesurer le complément C3c ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le complément C3c est mesuré par un test sanguin spécifique en laboratoire." } }, { "@type": "Question", "name": "Quels tests sont associés au C3c ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests de C3c sont souvent associés à des dosages de C3 et C4." } }, { "@type": "Question", "name": "Quand évaluer le C3c ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Le C3c est évalué lors de suspicion de maladies auto-immunes ou inflammatoires." } }, { "@type": "Question", "name": "Le C3c est-il un marqueur de maladie ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux anormaux de C3c peuvent indiquer des pathologies sous-jacentes." } }, { "@type": "Question", "name": "Quel rôle joue le C3c dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Le C3c aide à évaluer l'activité du système du complément dans diverses conditions." } }, { "@type": "Question", "name": "Quels symptômes sont liés à un faible C3c ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Un faible C3c peut entraîner des infections fréquentes et des inflammations." } }, { "@type": "Question", "name": "Un C3c élevé indique-t-il des symptômes ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Un C3c élevé peut être associé à des symptômes d'inflammation ou d'infection." } }, { "@type": "Question", "name": "Le C3c affecte-t-il la fatigue ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux anormaux de C3c peuvent contribuer à la fatigue liée à l'inflammation." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques au C3c ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Non, le C3c n'a pas de symptômes spécifiques, mais reflète l'état immunitaire." } }, { "@type": "Question", "name": "Le C3c est-il lié à des douleurs ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés de C3c peuvent être associés à des douleurs inflammatoires." } }, { "@type": "Question", "name": "Comment prévenir les anomalies du C3c ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Maintenir un mode de vie sain et gérer les maladies chroniques aide à prévenir les anomalies." } }, { "@type": "Question", "name": "Le vaccin influence-t-il le C3c ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Les vaccins peuvent stimuler le système immunitaire, influençant potentiellement le C3c." } }, { "@type": "Question", "name": "Y a-t-il des habitudes à éviter ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Éviter le tabagisme et une mauvaise alimentation peut aider à maintenir un C3c normal." } }, { "@type": "Question", "name": "Le stress affecte-t-il le C3c ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut perturber le système immunitaire et affecter le C3c." } }, { "@type": "Question", "name": "Des examens réguliers sont-ils nécessaires ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des examens réguliers peuvent aider à détecter des anomalies du C3c tôt." } }, { "@type": "Question", "name": "Comment traiter un faible C3c ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement dépend de la cause sous-jacente, souvent par immunothérapie." } }, { "@type": "Question", "name": "Des médicaments affectent-ils le C3c ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments immunosuppresseurs peuvent réduire les niveaux de C3c." } }, { "@type": "Question", "name": "Le C3c nécessite-t-il un suivi ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi régulier est recommandé pour surveiller les niveaux de C3c." } }, { "@type": "Question", "name": "Peut-on augmenter le C3c naturellement ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et un mode de vie sain peuvent soutenir le système immunitaire." } }, { "@type": "Question", "name": "Les transfusions affectent-elles le C3c ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les transfusions peuvent influencer les niveaux de C3c en fonction des composants." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec un C3c bas ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Un C3c bas peut entraîner des infections récurrentes et des maladies auto-immunes." } }, { "@type": "Question", "name": "Un C3c élevé cause-t-il des complications ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un C3c élevé peut être lié à des complications inflammatoires et des maladies chroniques." } }, { "@type": "Question", "name": "Le C3c affecte-t-il la guérison des blessures ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux anormaux de C3c peuvent retarder la guérison en perturbant l'inflammation." } }, { "@type": "Question", "name": "Y a-t-il des risques de thrombose liés au C3c ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés de C3c peuvent être associés à un risque accru de thrombose." } }, { "@type": "Question", "name": "Le C3c influence-t-il les maladies cardiovasculaires ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux anormaux de C3c peuvent être liés à un risque accru de maladies cardiovasculaires." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de C3c anormal ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les maladies auto-immunes, infections chroniques et certains médicaments augmentent le risque." } }, { "@type": "Question", "name": "L'âge influence-t-il le C3c ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'âge peut affecter les niveaux de C3c, souvent en raison de changements immunitaires." } }, { "@type": "Question", "name": "Le sexe joue-t-il un rôle dans le C3c ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des différences hormonales peuvent influencer les niveaux de C3c entre les sexes." } }, { "@type": "Question", "name": "Le mode de vie affecte-t-il le C3c ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent affecter le C3c." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils le C3c ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de maladies immunitaires peuvent augmenter le risque de C3c anormal." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 31/03/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Marinos C Dalakas

4 publications dans cette catégorie

Affiliations :
  • Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA. mdalakas@med.uoa.gr.
  • Neuroimmunology Unit, Department of Pathophysiology, Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece. mdalakas@med.uoa.gr.

Shruti Chaturvedi

4 publications dans cette catégorie

Affiliations :
  • Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Robert A Brodsky

4 publications dans cette catégorie

Affiliations :
  • Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Keith R McCrae

3 publications dans cette catégorie

Affiliations :
  • Division of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.

Martin Kohn

2 publications dans cette catégorie

Affiliations :
  • Institute of Medical Microbiology and Hospital Epidemiology, Medical School Hannover, Hannover, Germany.
Publications dans "Complément C3c" :

Christian Lanfermann

2 publications dans cette catégorie

Affiliations :
  • Institute of Medical Microbiology and Hospital Epidemiology, Medical School Hannover, Hannover, Germany.
Publications dans "Complément C3c" :

Robert Laudeley

2 publications dans cette catégorie

Affiliations :
  • Institute of Medical Microbiology and Hospital Epidemiology, Medical School Hannover, Hannover, Germany.
Publications dans "Complément C3c" :

Silke Glage

2 publications dans cette catégorie

Affiliations :
  • Institute for Laboratory Animal Science, Medical School Hannover, Hannover, Germany.
Publications dans "Complément C3c" :

Claudia Rheinheimer

2 publications dans cette catégorie

Affiliations :
  • Institute of Medical Microbiology and Hospital Epidemiology, Medical School Hannover, Hannover, Germany.
Publications dans "Complément C3c" :

Andreas Klos

2 publications dans cette catégorie

Affiliations :
  • Institute of Medical Microbiology and Hospital Epidemiology, Medical School Hannover, Hannover, Germany.
Publications dans "Complément C3c" :

Norimitsu Inoue

2 publications dans cette catégorie

Publications dans "Complément C3c" :

Steffen Thiel

2 publications dans cette catégorie

Affiliations :
  • Department of Biomedicine, Aarhus University, Aarhus C, Denmark.
Publications dans "Complément C3c" :

Dmitri Simberg

2 publications dans cette catégorie

Affiliations :
  • Translational Bio-Nanosciences Laboratory, Department of Pharmaceutical Sciences, Skaggs School of Pharmacy, University of Colorado Anschutz Medical Center, Aurora, CO, USA; Colorado Center for Nanomedicine and Nanosafety, University of Colorado Anschutz Medical Center, Aurora, CO, USA.
Publications dans "Complément C3c" :

Marloes A H M Michels

2 publications dans cette catégorie

Affiliations :
  • Radboud Institute for Molecular Life Sciences, Department of Pediatric Nephrology, Amalia Children's Hospital, Radboud University Medical Center, Nijmegen, Netherlands.

Per H Nilsson

2 publications dans cette catégorie

Affiliations :
  • Department of Immunology, University of Oslo and Oslo University Hospital Rikshospitalet, Oslo, Norway.
  • Linnaeus Centre for Biomaterials Chemistry, Linnaeus University, Kalmar, Sweden.
  • Department of Chemistry and Biomedical Sciences, Linnaeus University, Kalmar, Sweden.
Publications dans "Complément C3c" :

Evan M Braunstein

2 publications dans cette catégorie

Affiliations :
  • Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Eleni Gavriilaki

2 publications dans cette catégorie

Affiliations :
  • BMT Unit, Hematology Department, G. Papanicolaou Hospital, Thessaloniki, Greece.

Claudia Kemper

2 publications dans cette catégorie

Affiliations :
  • Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, United States.
Publications dans "Complément C3c" :

Anna Duval

2 publications dans cette catégorie

Affiliations :
  • Centre de Recherche des Cordeliers, Inserm UMR S1138, Paris, France.
  • Department of Nephrology Dialysis and Transplantation, University Hospital of Strasbourg, Strasbourg, France.
Publications dans "Complément C3c" :

Véronique Frémeaux-Bacchi

2 publications dans cette catégorie

Affiliations :
  • Centre de Recherche des Cordeliers, Inserm UMR S1138, Paris, France.
  • Service d'Immunologie, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.
Publications dans "Complément C3c" :

Sources (10000 au total)

Pharmacokinetics and tolerability of intranasal or intravenous administration of nalbuphine in infants.

Intranasal nalbuphine could be a safe, efficacious and non-invasive alternative to parenteral pain medication in infants. We aimed to assess pharmacokinetics (PK) and tolerability of intranasal and in... Prospective open-label study including infants 1-3 months of age admitted to the emergency department, receiving nalbuphine for procedural pain management. Patients were alternately allocated to a sin... Out of 52 study subjects receiving nalbuphine, 31 were eligible for NCA (11 intravenous, 20 intranasal). Median AUC... This is the first study investigating intranasal administration of nalbuphine in infants suggesting an intranasal bioavailability close to 50%. Non-invasive intranasal application was well tolerated. ... NCT03059511....

A case of intravenous iron administration resulting in cerebral edema expansion.

Iron plays an important role in the development of perihematomal edema (PHE) in the setting of intracerebral hemorrhage (ICH). Cerebral iron is increased via direct hemoglobin release in ICH, and seve... A 46-year-old woman was admitted to the hospital with acute moderate-to-severe TBI. Her head computed tomography (CT) scan showed bifrontal hemorrhagic contusions with mild PHE. She was started on hyp... We believe this is the first report of exacerbating PHE accompanied by clinical decline after intravenous iron administration in the setting of acute hemorrhagic brain contusions. Though the effects o...

Feasibility of periprocedural decision on the administration of intravenous contrast media in MRI for endometriosis.

To assess the feasibility of a periprocedural decision on the administration of intravenous contrast media in MRI for endometriosis and to evaluate the frequency and reasons of contrast administration... In this retrospective, descriptive cross-sectional single-center study all patients were included, who received a pelvic MRI for evaluation of endometriosis between April 2021 and February 2023. Frequ... 303 consecutive patients (mean age, 33.4 years +/- 8.3 [standard deviation]) were evaluated. Periprocedural decision on the administration of intravenous contrast media had been made in all cases. For... A periprocedural decision on the administration of contrast media in MRI for endometriosis is feasible with little effort. It allows the administration of contrast media to be avoided in most cases. I...

Optimization of intravenous administration of hydroxocobalamin in pediatric emergencies - HYDROX-OPTIMIS study.

Procedures to prepare and infuse intravenous drugs are poorly documented.... To determinate the optimal mode of hydroxocobalamin administration in children in emergency care.... We identified three modes of administration: (1) connect infusion tubing to the vial, start the infusion and interrupt it when the desired dose has been delivered; (2) remove from the vial the volume ... 25 nurses performed each of these three procedures for children weighting 15 and 30 kg. Speed and precision were primary end-points; ease, safety and drug economy were secondary end-points.... Mode 3 was the fastest (42[37-61] sec) followed by modes 1 and 2 (p < 0.05). Mode 3 was the most precise (100[100-100]%) followed by modes 1 and 2 (p = 0.001). Mode 3 was the easiest (10.0[9.0-10.0]) ... Taking the required volume from the vial and infuse directly was the fastest, the most precise, the easiest and most economical mode of administration. It should be recommended....

Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Patients With Multiple Myeloma at Mayo Clinic Infusion Centers.

Median duration of daratumumab (DARA) administration for treatment of multiple myeloma is 3-7 hours for the intravenous formulation (DARA IV) and 3-5 minutes for the subcutaneous formulation (DARA SC)... Time-based measurements were extracted using a scheduling/pharmacy software program that tracked patient movement through appointments for patients initiating DARA in Mayo Clinic infusion centers from... Median total clinic times were 2.7-3.0 hours shorter for DARA SC versus DARA IV. Median clinic times were highest at dose 1 and decreased with subsequent doses. Median total chair times were 2.7-2.8 h... Reduced clinic times were observed with DARA SC, indicating that use of DARA SC as a treatment option results in time savings that may free clinic resources. Furthermore, novel methods of electronic h...

Intravenous Opioid Administration During Mechanical Ventilation and Use After Hospital Discharge.

Guidelines recommend an analgesia-first strategy for sedation during mechanical ventilation, but associations between opioids provided during mechanical ventilation and posthospitalization opioid-rela... To evaluate associations between an intravenous opioid dose received during mechanical ventilation and postdischarge opioid-related outcomes in medical (nonsurgical) patients.... This retrospective cohort study evaluated adults receiving mechanical ventilation lasting 24 hours or more for acute respiratory failure and surviving hospitalization. Participants from 21 Kaiser Perm... Terciles of median daily intravenous fentanyl equivalents during mechanical ventilation.... The primary outcome was the first filled opioid prescription in 1 year after discharge. Secondary outcomes included persistent opioid use and opioid-associated complications. Secondary analyses tested... The study included 6746 patients across 21 hospitals (median age, 67 years [IQR, 57-76 years]; 53.0% male). Of the participants, 3114 (46.2%) filled an opioid prescription in the year prior to admissi... In this retrospective cohort study of patients receiving mechanical ventilation, opioids administered during mechanical ventilation were associated with opioid prescriptions following hospital dischar...

The Relationship between Rate and Volume of Intravenous Fluid Administration and Kidney Outcomes after Angiography.

Contrast-associated AKI may result in higher morbidity and mortality. Intravenous fluid administration remains the mainstay for prevention. There is a lack of consensus on the optimal administration s... We conducted a secondary analysis of 4671 PRESERVE participants who underwent angiographic procedures. Although fluid type was randomized, strategy of administration was at the discretion of the clini... The mean (SD) age was 70 (8) years, 94% of participants were male, and median (interquartile range) eGFR was 60 (41-60) ml/min per 1.73 m... We found that administration of a total volume of 1000 ml, starting at least 1 hour before contrast injection and continuing postcontrast for a total of 6 hours, is associated with a similar risk of a...

Pharmacokinetics and Safety of Vedolizumab Following Administration of a Single Intravenous Dose in Healthy Chinese Subjects.

Vedolizumab is a humanized monoclonal antibody, indicated for the treatment of moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD), that specifically binds to the α4β7 integr... Sixteen participants received a single IV infusion of vedolizumab (300 mg). Blood samples were collected to measure vedolizumab serum concentrations. The safety of all subjects was monitored.... The pharmacokinetic analysis showed that vedolizumab reached the maximum observed serum concentration (C... Vedolizumab was well tolerated in healthy Chinese subjects when administered as a single-dose IV 300 mg infusion. In this study, the rate of AVA positivity was 37.5%, which occurred near the end of th... http://www.chinadrugtrials.org.cn : CTR20171528....

Epinephrine administration in adults with out-of-hospital cardiac arrest: A comparison between intraosseous and intravenous route.

The benefits and risks of the intraosseous (IO) route for vascular access in patients with out-of-hospital cardiac arrest (OHCA) remain controversial. This study compares the success rates of establis... This was a retrospective study conducted by the San-Min station of Taoyuan Fire Department. Data for IV access were collected between January 1, 2020, and December 31, 2020. Data for IO access were co... A total of 112 adult patients were enrolled in the analysis, including 71 men and 41 women, with an average age of 67 years. There were 90 IV access cases and 22 IO access cases. The groups were compa... The IO route was significantly associated with higher success rates of route establishment, epinephrine administration, and shorter time-to-epinephrine in the prehospital resuscitation of adult patien...